Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Continuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety and tolerability profile as…